Mon Mar 24 03:15:32 UTC 2025: ## New Drug Trial Aims to Extend Dog Lifespans
**Denver, CO** – A groundbreaking clinical trial is underway in the US, aiming to significantly extend the lifespan of dogs. Loyal, a San Francisco-based animal health company, is conducting the double-blind placebo-controlled STAY study involving over 1,000 senior dogs. The study, detailed in a recent CBS News report, seeks to evaluate a novel drug designed to combat the accelerated aging process in canines.
The four-year study requires a significant commitment from dog owners. Eligible dogs must be at least 10 years old and weigh 14 pounds or more. Owners must agree to transfer their dog’s primary care to one of the participating clinics and commit to regular checkups – six visits in the first year, and two annually thereafter.
Alex Robb, medical director of Goodheart Animal Health Center (one of several participating clinics), explained the process: “Once enrolled and deemed safe, dogs take the medication daily for up to four years.” The double-blind nature of the study, where neither owners nor administrators know which dogs receive the actual drug, ensures unbiased results.
Researchers believe dogs’ shorter lifespans are linked to their higher metabolic rate, leading to faster aging. While veterinary medicine has advanced, it hasn’t kept pace with human medicine in extending lifespans. This trial aims to address this disparity.
Loyal hopes to submit the study’s findings to the FDA for approval, potentially seeking conditional approval by the end of the year, pending sufficient data. The company has already seen success in preclinical and pilot studies. The study is currently recruiting participants. Interested owners can contact participating clinics for more information.
First Piper 